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Antiretroviral drugs are involved in the occurrence of adverse effects. In Côte d'Ivoire, HIV1 treatment 
protocols are non-nucleoside reverse transcriptase inhibitors based. No study has been undertaken in the 
country about cardiovascular risk. Thus, the objectiv  of our study was to assess the prevalence of biological 
abnormalities and clinical markers of cardiovascular risk during antiretroviral therapy. We conducted a 
prospective cross-sectional study with 238 patients who were on antiretroviral treatment including non-
nucleoside reverse transcriptase inhibitors for at le st 6 months in the Pneumophtisiology department of the 
university hospital of Cocody (Abidjan). Metabolic syndrome was determined according to NCEP-ATP III 
criteria. Biological parameters investigated were: tiglyceride, HDL cholesterol and LDL, glucose and clini al 
parameters: blood pressure and waist circumference. Eleven patients (4.62%) have a metabolic syndrome, 
17.6% had hypertriglyceridemia. An increase in LDL cholesterol and lower HDL-cholesterol were found in 
both cases in 13.9% of patients and an atherogenic index greater than 4.5 in 5% of patients. Hyperglycemia 
occurred during antiretroviral therapy in 28% of the study population. Patients who developed hypertension 
and increased waist circumference during antiretroviral therapy were 9.75% and 15.5% respectively.  Our
results testify to the potential existence of a cardiovascular risk during the non-nucleoside inhibitor used. 
© 2015 International Formulae Group. All rights reserved. 
 




Antiretroviral (ARV) drugs in the 
treatment of HIV infection have dramatically 
changed the natural history of the disease; 
significantly reducing the morbidity and 
mortality rate of this disease. Despite proven 
efficacy of the combination therapy, these 
molecules are involved in the occurrence of 
adverse effects that could have a biological 
and / or clinical effect (Awah and Agughasi 
2011; Chow et al., 2003; DAD 2003; Jeroen et 
al., 2012; Muhammad et al., 2013, Roula et 
al., 2000), and occur immediately after 
initiation of treatment, or months or years of 
ARV treatment. These side effects 
constituting components of the metabolic 




syndrome can lead to over a long period 
complications of cardiovascular disease, the 
leading causes of death worldwide (Currier 
2002). These metabolic complications 
constitute metabolic syndrome (MS), 
including abnormal fat distribution, 
hypertension, dyslipidemia (hypertriglyce-
ridemia, low HDL-cholesterol) and insulin 
resistance. An increase of approximately 26% 
of the risk of myocardial infarction has been 
reported in patients on highly active 
antiretroviral therapy (HAART) (Jeroen et al., 
2012). 
In Côte d'Ivoire, HIV1 first line 
treatment protocols are protocols including 
first line two nucleoside reverse transcriptase 
inhibitors and non-nucleoside reverse 
transcriptase inhibitor. These protocols have 
changed the prognosis with improved life 
expectancy of patients infected with HIV. 
However, few studies describe the biological 
and clinical abnormalities prelude to 
cardiovascular complication during 
antiretroviral therapy. So, in order to detect 
cardiovascular risk involving ARVs, we 
conducted a clinical study to assess the 
prevalence of biological abnormalities and 
clinical markers of cardiovascular risk during 
antiretroviral therapy. Specifically, our 
purpose was to determine the prevalence of 
metabolic syndrome and the frequency of its 
determinants on the one hand and find a 
correlation between determinants of metabolic 
syndrome and antiretroviral therapy on the 
other hand. 
 
MATERIALS AND METHODS 
This is a prospective cross-sectional 
study based on a single assessment conducted 
during patient routine follow up visit. It took 
place in the care center for HIV patients of the 
University Teaching Hospital of Cocody. This 
study is authorized by the scientific medical 
direction of the University Teaching Hospital 
of Cocody. 
The study began in February and ended 
in   July  2012.   The   inclusion  concerned: 
HIV1 + patients under HAART for at least 6 
months aged 15 years and above; patients 
regularly monitored with a favorable result 
and agreed to join the study. 
Were excluded in our study HIV 
patients in second-line treatment (receiving 
PI), HIV + patients with recent infections, 
patients on anti-lipid treatment, steroids or 
hormone therapy, patients with kidney failure 
or liver cytolysis, patients with comorbidity 
(hypertension, obesity, diabetes). 
Our study included 238 HIV + patients 
on HAART. During the usual scheduled visit, 
according national recommendations, the 
patients fasting blood sample were collected. 
Venous blood taken at the elbow was 
collected in EDTA tube and two dry tubes, 
one of which was used in our study. 
Then, the patients were taken to a room 
where a series of questions were asked in 
order to fill the survey form. The survey form 
included patient identification, socio-
demographic parameters, the initial clinical 
and biological assessment, the current clinical 
and laboratory assessment, blood pressure was 
measured after 5 minutes, the weight was 
measured on a mechanical balance, abdominal 
obesity was assessed by measuring waist 
circumference (abnormal value: greater than 
or equal to 102 cm for men and 88 cm for 
women), the body mass index (BMI) was 
calculated using the following formula: 
weight (kg) / height (m) 2 (values: BMI ˂ 
18.5: Insufficient weight, BMI between 18.5 
and 24.9: Normal; BMI between 25 and 29.9: 
Overweight; BMI between 30 and 34.9: 
Obesity) 
The biological analyses of samples 
were performed at the Laboratory of 
Biochemistry of the University Teaching 
Hospital of Cocody. Fasting Venous blood 
was collected (10-12 hours). These samples 
were collected on the one hand in dry tubes 
(without anticoagulant) and on the other hand 
in gray tubes with anticoagulants (sodium 
fluoride). Serum was aliquoted after 
centrifugation (3000 rpm / 3 min). 




Carbohydrate and lipid profile 
(glucose, total cholesterol, HDL-cholesterol, 
triglyceride), were determined on the serum 
by routine enzymatic colorimetric method 
according to Trinder on analyzer controller 
HITACHI 902. The LDL-cholesterol was 
calculated by Friedwald formula: LDL-C = 




The statistical analysis of the data was 
realized by means of the software SPSS 17.0. 
The averages are compared with Anova and 
the qualitative variables (in %) are compared 
with the test of Khi square; with p< 0.05. 
 
RESULTS 
The average age of the population 
studied is 42.78 years ± 10.438 years with a 
minimum age of 16 years and a maximum age 
of 74 years. The age group 26 to 55 years 
represents 84.90% of the population studied 
(Figure 1). The sex ratio is 0.47 with a female 
predominance (68%).  
The most prescribed protocols are  
AZT / 3TC / EFV and AZT / 3TC / NVP with 
the respective proportions of 59.24% and 
24.78% (Table 1). 
The duration of the treatment is of 6 
months at least and of 134 months at most 
with an average of 55.21 ± 30.693 months. 
In our results, it appears that 11 
patients or about 4.62% of the study 
population have a MS according to NCEP-
ATP III criteria with at least three after ARV 
treatment with NNRTIs at least 6 months. 
Table 2 reported frequency of metabolic 
syndrome parameters. About lipids 
abnormalities, 17.6% of patients had 
hypertriglyceridemia. An increase in LDL 
cholesterol and lower HDL-cholesterol were 
found in both cases with 13.9% of the study 
population and an atherogenic index greater 
than 4.5 in 5% of patients’ population. 
Hyperglycemia occurred during antiretroviral 
therapy in 56 patients that is 23.5% of the 
study population. Clinically, the percentage of 
patients who developed blood pressure up to 
130/85 mm Hg and increased waist 
circumference during antiretroviral therapy 
was 13.9% and 15.5% respectively. No 
significant differences in these abnormalities 
were found between Nevirapine based 
protocol and Efavirenz-based protocol 
(p>0.05) (Table 3). 
 
 
Table 1: Antiretroviral treatment protocols in the study population. 
 
Protocols Number Proportion % 
AZT/3TC/EFV 141 59.25 
AZT/3TC/NVP 59 24.79 
TDF/FTC/EFV 15 6.30 
D4T/3TC/EFV 9 3.78 
TDF/3TC/EFV 8 3.36 
D4T/3TC/NVP 4 1.68 
AZT/3TC/ABC 1 0.42 
TDF/FTC/NVP 1 0.42 
Total 238 100 
ABC = Abacavir ;   FTC = Emtricitabine ; AZT = Zidovudine ;     NVP = Nevirapine ;         








Table 2:  Frequency of metabolic syndrome parameters. 
 
Parameters Number (n =238) Percentages (%) 
Triglycerides > 1.5 g/l 42 17.6% 
HDL-c ˂ 0.4 g/l in man ˂ 0.5 g/l in woman 33 13.9% 
BP ˃  130/85 mmHg 33 13.9% 
Glucose ˃  1.1 g/l 56 23.5% 
Elevated waist circumference 38 16% 
HDL = High density lipoprotein;   Bp = Arterial blood pressure 
 
 
Table 3: Biological and clinical abnormalities and antiretroviral treatment protocols. 
 
Parameters  EFV-pro NVP-pro p OR, IC95 % 
AI > 4.5 7 (5.7%) 2 (4.1%) 0.501 1.093 
0.760 – 1.571 < 4.5 116 (94.3%) 47 (95.9%) 
Triglycerides > 1.5 g/l 24 (19.5%) 9 (18.4%) 0.525 1.021 
0.808 – 1.291 ≤ 1.5 g/l 99 (80.5%) 40 (81.6%) 
HDL-c low 17 (13.8%) 7 (14.3%) 0.555 0.989 
0.750 – 2.016 Normal 106 (86.2%) 42 (85.7%) 
Waist circumference elevated 18 (14.6%) 12 (24.5%) 0.096 0.811 
0.596 – 1.104 Normal 105 (85.4%) 37 (75.5%) 
Fasting glucose > 1.1 g/l 53 (43.1%) 26 (53.1%) 0.155 0.891 
0.735 – 1.082 ≤ 1.1 g/l 70 (56.9%) 23 (46.9%) 
Bp (mmHg) ˃130/85 19 (15.4%) 6 (12.2%) 0.392 1.074 
0.842 – 1.371 ˂130/85 104 (84.6%) 43 (87.8%) 
There is no significant differences in parameters between NVP-pro and NVP-pro (p>0.05). ; HDL = High density 
lipoprotein; NVP-pro = Nevirapine base Protocol; AI = atherosclerosis Index; EFV-pro = Efavirenz base protocol; BP = 

















The metabolic syndrome (MS) as 
defined according to the National Cholesterol 
Education Program Adult Treatment Panel III 
(NCEP-ATP III), includes at least three of the 
following five biological and / or clinical 
abnormalities following: waist circumference 
greater than 102 cm in men and greater than 
88 cm in women; triglycerides higher than  
1.5 g / l; HDL-cholesterol less than 0.4 g / L 
in men and less than 0.5 g / l in women; blood 
pressure greater than 130 / 85 mmHg; Fasting 
glucose greater than 1.1 g / l. The rate of MS 
in our study (4.62%) was similar to that found 
by Hauhouot et al. (2008) in an apparently 
healthy population. This rate is lower than the 
prevalence observed in a study in Cotonou 
(IMEA, 2007) establishing a diagnosis of 
metabolic syndrome in 13% of patients on 
HAART without PI for a period of 15 months 
of average and in a study in Kano (Nigeria) 
where the prevalence reach 21% (Muhammad 
et al 2013). Elsewhere, in Western countries, 
the prevalence of metabolic syndrome 
reaching values of 17-42% is found mainly in 
PI-based ARV treatment (Jeroen et al., 2012). 
In our study, the most common ARV 
regimens were AZT / 3TC / NVP (24.78%) 
and AZT / 3TC / EFV (59.24%). Among the 
11 patients with metabolic syndrome majority 
of them about 72.73% received ARV 
treatment with EFV and 27.27% were on NVP 
based regimen. Seeking a correlation between 
the occurrence of metabolic syndrome and 
ARV regimens, it is clear that there is no 
significant difference between the ARV 
regimens in patients with and without 
metabolic syndrome. MS is established as an 
independent predictor and marker of 
morbidity and cardiovascular mortality 
(Isomaa et al., 2001), 4.62% of patients in our 
study would be exposed to cardiovascular 
disease. 
Although the prevalence of MS is 
relatively low in our study, we investigated 
the frequency of these determinants because 
they each represent a potential factor for 
cardiovascular disease caused by antiretroviral 
therapy. The body mass index is typically 
used to assess cardiovascular risk. But, the 
simple measurement of waist circumference, 
easy to make, is equally relevant for 
predicting cardiovascular risk. Our study 
shows that approximatively 16% of the 
population has an increased waist 
circumference and no relationship was 
established with the occurrence of MS. Also, 
no significant relationship was found between 
the waist circumference and the ARV 
protocol. Laiz et al. (2011) reported a high 
rate (17%) of increased waist circumference 
in women HIV + patients. 
Glucose level ˃  1.1 g / l observed in a 
large portion of our sample (23.5%) showed 
the presence of an insulin resistance 
frequently encountered in patients with HIV 
infection. This insulin resistance could be as a 
result of direct effects of antiretrovirals 
through their mitochondrial toxicity, also HIV 
infection and fat redistribution. Studies 
investigating cases of diabetes in patients 
under HAART in sub-Saharan Africa are rare. 
Elsewhere in the Western countries, Brown et 
al. (2005) found a value of 14%; study 
conducted by Hadigan et al. (2001) showed 
35% cases of hyperglycemia in patients with 
ARV protocols PI, NRTIs and / or NNRTIs. 
Among the inhibitors of reverse transcriptase, 
D4T and EFV are involved in the appearance 
of type-2 diabetes in HIV + patients (Jeroen et 
al., 2012). In our study, we did not find any 
significant relationship between ARV 
regimens and glycemic ˃ 1.1 g / l. Thus NVP 
and EFV could be equally involved in the 
occurrence of diabetes under HAART. 
The introduction of ARVs in HIV + 
patients has led to marked changes in lipid 
profile (Jeroen et al 2012) involving an 
increase in triglycerides and LDL cholesterol, 
and decreased HDL-cholesterol (Carr, 2003; 
Grinspoon and Carr, 2005; Akawu et al., 
2013). In our study, 17.6% of patients 
reported presented elevated triglycerides. An 
increase in LDL cholesterol, and reduced 
HDL cholesterol were found in 13.9% both 
cases of the study population. Besides HIV, 




ARVs have been widely associated to lipid 
abnormalities. In a study conducted in 
Burkina Faso (Sakandé et al., 2012), the 
authors highlight, especially in men, an 
increase in total cholesterol and triglycerides 
correlated; positively to the presence of ARV 
treatment with NVP over a period ranging 
from 1 to 5 years. An increase in triglycerides 
was also observed in a study conducted in 
Nigeria (Awah and Agughasi, 2011). In a 
large cross-sectional study conducted by DAD 
(2003), the proportion of 
hypercholesterolemia, hypertriglyceridemia, 
and low HDL-cholesterol were 10-27%, 23-
40%, and 19-27%, respectively, depending on 
antiretroviral treatment. In our study majority 
of patients with dyslipidemia took EFV based 
ARV treatment (59.24%). When comparing 
ARV regimens in patients without 
dyslipidemia to those with dyslipidemia, no 
significant correlation between ARV 
treatment protocol and dyslipidemia was 
found. EFV and NVP show no significant 
difference in their involvement in the 
development of lipid abnormalities. Our 
results are in contrast to those of Leth et al. 
(2004) who, in their study, reported that the 
EFV is more associated to a more pronounced 
elevation of cholesterol and triglycerides that 
NVP after treatment duration of 48 weeks. 
This advantage of the NVP over EFV is also 
reported by Tashima et al. (2003) in a study in 
which it appears that the replacement of a PI 
by NVP is associated with a significant 
decrease in triglycerides and cholesterol, an 
effect rarely observed with EFV. 
Furthermore, randomized studies 
conducted by Negredo et al. (2002) and Fisac 
et al. (2005) compared NVP and EFV and 
confirm the superiority of NVP over EFV in 
the control of lipid abnormalities due to 
treatment with a PI. Knowing that the effect of 
dyslipidemia on the increase in cardiovascular 
disease, particularly coronary heart is well 
established (Rossi et al., 2009), these lipid 
abnormalities manifested in our study 
regardless of the ARV treatment protocols 
used, would demonstrate the potential 
existence of a cardiovascular risk. 
The atherogenic index (AI) is 
determined by the total Cholesterol / HDL 
ratio greater than 4.5, our study highlights an 
index above normal values in 5% of patients. 
There is therefore a potential atherogenic risk 
in our study population. In patients with MS, 
16.7% had a high AI against 4% in patients 
without MS. Thus the risk of cardiovascular 
disease was significantly higher in patients 
with MS. Hadigan et al. (2001) in the United 
States reported the presence of an atherogenic 
risk during HIV infection. In his study, 100% 
of patients presented a high AI. This high rate 
is due to fat redistribution and insulin 
resistance that HIV patients with 
lipodystrophy have. Hence, lipid 
abnormalities associated with MS contribute 
to increase in the atherogenic risk in these 
patients on ARV dominated by NNRTI-based 
regimens. 
Before the advent of HAART, 
hypertension was often reported in patients 
infected with HIV (Iwuala, 2008). Recent 
studies highlight hypertension increasingly 
observed in patients infected with HIV on 
antiretroviral therapy (Gazzaruso et al., 
2003; Jung et al., 2004). Blood pressure up 
than 130/85 mmHg was found in 13.9% of our 
study population receiving ARV treatment. 
Iwuala et al. (2008) in Nigeria reported a 
value of 51.2% of hypertension cases in HIV+ 
patients mainly on NNRTI-based HAART. 
Muhammad et al. (2013) reported a 
prevalence of 17% of hypertension cases in 
HIV patients mainly on NNRTI-based 
HAART during 6-84 months. In Western 
countries, many studies showed hypertension 
proportion among HIV patients on HAART 
ranging from 13% to 34% (Gazzaruso et al., 
2003; Jung et al., 2004; Bergersen et al., 2003; 
Medina-Torne et al., 2012; Savès et al., 2003). 
ARV protocols found in hypertensive 
patients (BP>130/85 mmHg) in our study 
were 12.2% for NVP based and 15.4% on 
EFV based. When comparing in our study the 
ARV regimens in hypertensive patients and 




those in non-hypertensive patients, it was 
clear that there was no significant link 
between High Blood Pressure and ARV 
treatment protocol. Cohort studies seeking a 
correlation between HAART and 
hypertension produce divergent results. A 
large cross-sectional study showed a moderate 
rise in blood pressure associated with NNRTI 
based ARV treatment (Chow et al., 2003). 
Several studies have found no effect of 
HAART on blood pressure, while some 
studies reported concerning PI, either a 
decrease (Thiebaut et al., 2005), or an increase 
(Cattelan et al., 2001; Crane et al., 2006) of 
the incidence of hypertension. These 
differences may be partly explained due to 
weight gain after antiretroviral therapy (Crane 
et al., 2006) but also by the duration of ARV 
treatment since Seaberg et al. (2005) showed 
that ARV treatment for a period of 20 years is 
associated to an increase in blood pressure 
while at the end of 5 years of ARV treatment, 
there is no significant increase in the blood 
pressure. Although the correlation of ARV 
and hypertension is not established in our 
study, the presence of hypertension is an 
indication of cardiovascular risk in HIV + 
patients under HAART. 
 
Conclusion 
Knowing that these biological and 
clinical abnormalities are highly involved in 
the occurrence of cardiovascular diseases, 
particularly coronary, our results testify to the 
potential existence of a cardiovascular risk 
during non-nucleoside inhibitor used. 
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